Table 3 Relationship between different LC3B staining patterns and clinicopathological parameters in oesophageal adenocarcinoma patients. Statistical analysis was carried out using chi-squared test (* p < 0.05)
LC3B Cytoplasmic staining | LC3B Globular staining | |||||
|---|---|---|---|---|---|---|
Negative n=88 | Positive n=56 | p–value | Negative n=86 | Positive n=58 | p-value | |
Differentiation (unknown n = 2) | ||||||
Well | 5 (5.8%) | 1 (1.8%) | 0.142 | 5 (6%) | 1 (1.7%) | |
Moderate | 36 (41.9%) | 17 (30.4%) | 33 (39.3%) | 20 (34.5%) | ||
Poor | 45 (52.3%) | 38 (67.9%) | 46 (54.8%) | 37 (63.8%) | 0.343 | |
Histological T staging | ||||||
T I | 12 (13.6%) | 5 (8.9%) | 12 (14%) | 5 (8.6%) | ||
T II | 19 (21.6%) | 8 (14.3%) | 18 (20.9%) | 9 (15.5%) | ||
T III | 55 (62.5%) | 40 (71.4%) | 53 (61.6%) | 42 (72.4%) | ||
T IV | 2 (2.3%) | 3 (5.4%) | 0.397 | 3 (3.5%) | 2 (3.4%) | 0.575 |
Clinical T staging (unknown n = 12) | ||||||
T I | 3 (3.8%) | 0 (0%) | 2 (2.5%) | 1 (1.9%) | ||
T II | 8 (10.1%) | 3 (5.7%) | 10 (12.7%) | 1 (1.9%) | ||
T III | 67 (84.8%) | 49 (92.5%) | 65 (82.3%) | 51 (96.2%) | ||
T IV | 1 (1.3%) | 1 (1.9%) | 0.382 | 2 (2.5%) | 0 (0%) | 0.089 |
Lympho-vascular invasion (unknown n = 2) | ||||||
Negative | 33 (38.4%) | 16 (28.6%) | 0.230 | 33 (39.3%) | 16 (27.6%) | |
Positive | 53 (61.6%) | 40 (71.4%) | 51 (60.7%) | 42 (72.4%) | 0.149 | |
Recurrence | ||||||
Negative | 46 (52.3%) | 19 (33.9%) | 0.031* | 46 (53.5%) | 19 (32.8%) | |
Positive | 42 (47.7%) | 37 (66.1%) | 40 (46.5%) | 39 (67.2%) | 0.014* | |
Mandard (unknown n = 8) | ||||||
Response | 7 (8%) | 3 (5.5%) | 0.715 | 7 (8%) | 3 (5.5%) | |
No response | 76 (86.4%) | 50 (90.9%) | 76 (86.4%) | 50 (90.9%) | 0.643 | |